Boothbay Fund Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-55,400
Closed -$13.5M – 1588
2024
Q2
$13.5M Buy
55,400
+21,400
+63% +$3.38M 0.32% 42
2024
Q1
$5.08M Sell
34,000
-5,700
-14% -$951K 0.1% 221
2023
Q4
$7.6M Buy
+39,700
New +$6.76M 0.19% 102
2022
Q4
– Sell
-34,800
Closed -$6.97M – 1974
2022
Q3
$6.97M Sell
34,800
-1,500
-4% -$286K 0.17% 100
2022
Q2
$5.29M Buy
36,300
+20,500
+130% +$2.91M 0.14% 165
2022
Q1
$2.58M Sell
15,800
-3,900
-20% -$594K 0.06% 468
2021
Q4
$3.34M Buy
19,700
+1,900
+11% +$353K 0.08% 308
2021
Q3
$3.36M Sell
17,800
-4,200
-19% -$788K 0.09% 261
2021
Q2
$3.73M Buy
+22,000
New +$3.22M 0.12% 189
2020
Q2
– Sell
-310
Closed -$3.37M – 946
2020
Q1
$3.37M Buy
+310
New +$35.8K 0.28% 83
2019
Q4
– Sell
-192
Closed -$1.54M – 835
2019
Q3
$1.54M Buy
+192
New +$15.2K 0.14% 201
2018
Q4
– Sell
-115
Closed -$1.01M – 647
2018
Q3
$1.01M Buy
+115
New +$11.6K 0.1% 208
2017
Q4
– Sell
-25
Closed -$294K – 701
2017
Q3
$294K Buy
+25
New +$2.13K 0.05% 379

Other funds holding ALNY

Boothbay Fund Management's ALNY Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 6,235 shares worth $1.88M. The stake represents 0.02% of the portfolio and ranks #756 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in ALNY as recently as Q2 2025.

Boothbay Fund Management first reported a position in ALNY in Q2 2017 and has held it in 12 quarters since. The position peaked at $6.27M in Q2 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Boothbay Fund Management held 6,235 shares of Alnylam Pharmaceuticals worth $1.88M as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Boothbay Fund Management position in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.02% of Boothbay Fund Management's portfolio in Q2 2026, its #756 holding.
  • Boothbay Fund Management first reported a position in Alnylam Pharmaceuticals in Q2 2017 and has held it in 12 quarters since.
  • Boothbay Fund Management's Alnylam Pharmaceuticals position peaked at $6.27M in Q2 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.